Cimetidine (oral)

Cimetidine (oral)
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gloria Picoy [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Cimetidine (oral) is an antacid that is FDA approved for the treatment of duodenal ulcer disease, erosive esophagitis, gastric ulcer, systemic mast cell disease, Zollinger-Ellison syndrome.. Common adverse reactions include gynecomastia.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Short-term treatment of active duodenal ulcer

• Dosage: 800 mg at bedtime
• Most patients heal within 4 weeks and there is rarely reason to use cimetidine tablets at full dosage for longer than 6 to 8 weeks.
• Concomitant antacids should be given as needed for relief of pain.
• However, simultaneous administration of cimetidine tablets and antacids is not recommended, since antacids have been reported to interfere with the absorption of cimetidine.

Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer

• Patients have been maintained on continued treatment with cimetidine tablets 400 mg at bedtime for periods of up to 5 years.

Short-term treatment of active benign gastric ulcer

• 800 mg at bedtime
• 300 mg 4 times a day with meals and at bedtime
• There is no information concerning usefulness of treatment periods of longer than 8 weeks.

Erosive gastroesophageal reflux (GERD)

• Dosage: 1600 mg daily in divided doses (800 mg twice daily or 400 mg 4 times daily) for 12 weeks
• Erosive esophagitis diagnosed by endoscopy.
• Treatment is indicated for 12 weeks for healing of lesions and control of symptoms. * The use of cimetidine tablets beyond 12 weeks has not been established.

The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas)

• Dosage: 300 mg 4 times a day with meals and at bedtime

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Cimetidine in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Cimetidine in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Cimetidine (oral) FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Cimetidine in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Cimetidine in pediatric patients.

Contraindications

There is limited information regarding Cimetidine (oral) Contraindications in the drug label.

Warnings

There is limited information regarding Cimetidine (oral) Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Cimetidine (oral) Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Cimetidine (oral) Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Cimetidine (oral) Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Cimetidine (oral) in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Cimetidine (oral) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Cimetidine (oral) during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Cimetidine (oral) in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Cimetidine (oral) in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Cimetidine (oral) in geriatric settings.

Gender

There is no FDA guidance on the use of Cimetidine (oral) with respect to specific gender populations.

Race

There is no FDA guidance on the use of Cimetidine (oral) with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Cimetidine (oral) in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Cimetidine (oral) in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Cimetidine (oral) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Cimetidine (oral) in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Cimetidine (oral) Administration in the drug label.

Monitoring

There is limited information regarding Cimetidine (oral) Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Cimetidine (oral) and IV administrations.

Overdosage

There is limited information regarding Cimetidine (oral) overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Cimetidine (oral) Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Cimetidine (oral) Mechanism of Action in the drug label.

Structure

There is limited information regarding Cimetidine (oral) Structure in the drug label.

Pharmacodynamics

There is limited information regarding Cimetidine (oral) Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Cimetidine (oral) Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Cimetidine (oral) Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Cimetidine (oral) Clinical Studies in the drug label.

How Supplied

There is limited information regarding Cimetidine (oral) How Supplied in the drug label.

Storage

There is limited information regarding Cimetidine (oral) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Cimetidine (oral) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Cimetidine (oral) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Cimetidine (oral) Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Cimetidine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Cimetidine (oral) Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Cimetidine (oral) Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

Cimetidine (oral)

Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]	US FDA: Cimetidine
Pregnancy category	AU: B1 US: B (No risk in non-human studies)
Routes of administration	Oral, parenteral
ATC code	A02BA01 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) OTC/℞-only (U.S., dose-dependent)
Pharmacokinetic data
Bioavailability	60–70%
Protein binding	15–20%
Metabolism	Hepatic
Elimination half-life	2 hours
Excretion	Renal
Identifiers
IUPAC name 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl) methylsulfanyl]ethyl]guanidine
CAS Number	51481-61-9
PubChem CID	2756
DrugBank	APRD00568
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C10H16N6S
Molar mass	252.34 g/mol

WikiDoc Resources for Cimetidine (oral)
Articles
Most recent articles on Cimetidine (oral) Most cited articles on Cimetidine (oral) Review articles on Cimetidine (oral) Articles on Cimetidine (oral) in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cimetidine (oral) Images of Cimetidine (oral) Photos of Cimetidine (oral) Podcasts & MP3s on Cimetidine (oral) Videos on Cimetidine (oral)
Evidence Based Medicine
Cochrane Collaboration on Cimetidine (oral) Bandolier on Cimetidine (oral) TRIP on Cimetidine (oral)
Clinical Trials
Ongoing Trials on Cimetidine (oral) at Clinical Trials.gov Trial results on Cimetidine (oral) Clinical Trials on Cimetidine (oral) at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cimetidine (oral) NICE Guidance on Cimetidine (oral) NHS PRODIGY Guidance FDA on Cimetidine (oral) CDC on Cimetidine (oral)
Books
Books on Cimetidine (oral)
News
Cimetidine (oral) in the news Be alerted to news on Cimetidine (oral) News trends on Cimetidine (oral)
Commentary
Blogs on Cimetidine (oral)
Definitions
Definitions of Cimetidine (oral)
Patient Resources / Community
Patient resources on Cimetidine (oral) Discussion groups on Cimetidine (oral) Patient Handouts on Cimetidine (oral) Directions to Hospitals Treating Cimetidine (oral) Risk calculators and risk factors for Cimetidine (oral)
Healthcare Provider Resources
Symptoms of Cimetidine (oral) Causes & Risk Factors for Cimetidine (oral) Diagnostic studies for Cimetidine (oral) Treatment of Cimetidine (oral)
Continuing Medical Education (CME)
CME Programs on Cimetidine (oral)
International
Cimetidine (oral) en Espanol Cimetidine (oral) en Francais
Business
Cimetidine (oral) in the Marketplace Patents on Cimetidine (oral)
Experimental / Informatics
List of terms related to Cimetidine (oral)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]

Overview

Cimetidine (INN) (Template:PronEng) is a histamine H₂-receptor antagonist that inhibits the production of acid in the stomach. It is largely used in the treatment of heartburn and peptic ulcers. It is marketed by GlaxoSmithKline under the trade name Tagamet (sometimes Tagamet HB or Tagamet HB200) and was approved by the Food & Drug Administration for prescriptions starting January 1, 1979.

Clinical use

Main article:H2-receptor antagonist

History and development

Cimetidine was the prototypical histamine H₂-receptor antagonist from which the later members of the class were developed. Cimetidine was the culmination of a project at Smith, Kline & French (SK&F; now GlaxoSmithKline) to develop a histamine receptor antagonist to suppress stomach acid secretion.

At the time (1964) it was known that histamine was able to stimulate the secretion of stomach acid, but also that traditional antihistamines had no effect on acid production. In the process, the SK&F scientists also proved the existence of histamine H₂-receptors.

The SK&F team used a rational drug-design structure starting from the structure of histamine - the only design lead, since nothing was known of the then hypothetical H₂-receptor. Hundreds of modified compounds were synthesised in an effort to develop a model of the receptor. The first breakthrough was N^α-guanylhistamine, a partial H₂-receptor antagonist. From this lead the receptor model was further refined and eventually led to the development of burimamide, the first H₂-receptor antagonist. Burimamide, a specific competitive antagonist at the H₂-receptor 100-times more potent than N^α-guanylhistamine, proved the existence of the H₂-receptor.

Burimamide was still insufficiently potent for oral administration and further modification of the structure, based on modifying the pKa of the compound, lead to the development of metiamide. Metiamide was an effective agent, however it was associated with unacceptable nephrotoxicity and agranulocytosis. It was proposed that the toxicity arose from the thiourea group, and similar guanidine-analogues were investigated until the ultimate discovery of cimetidine.

Other uses

There have been two studies relating to the use of Cimetidine for treatment of warts in children. According to the studies, a daily dosage of 400mg of Cimetidine can remove over 200 warts from a 15 year old child.[4]

Another study by Yokoyama et al used Cimetidine for the treatment of Chronic Calcifying Tendonitis of the shoulder. The small scale study took 16 individuals with calcifying tendonitis in one shoulder, all of which had previously attempted other forms of therapy including steroid injection and arthroscopic lavage. During the course of the study 10 patients reported an elimination of pain and 9 displayed a complete disappearance of Calcium deposits. With results being on a small scale, it has been recommended that Cimetidine, for the treatment of chronic calcifying tendonitis of the shoulder, be opened to large scale clinical trials. [5]

Cimetidine has also been reported for use in treatment of colorectal cancer - it is however not approved in the US by the FDA for cancer treatment.

Shortcomings and side effects

Cimetidine is a known inhibitor of many isozymes of the cytochrome P450 enzyme system (specifically CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4). This inhibition forms the basis of the numerous drug interactions that occur between cimetidine and other drugs. For example, cimetidine may decrease metabolism of some drugs, such as those used in hormonal contraception. Cimetidine interferes with metabolism of the hormone estrogen, enhancing estrogen activity. In women, this can lead to galactorrhea, whereas in men gynecomastia and a reduced sperm count can result. Adverse drug reactions were also found to be relatively common with Cimetidine, including interactions with the antimalarial medication Hydroxychloroquine.

The development of longer-acting H₂-receptor antagonists with reduced adverse effects such as ranitidine proved to be the downfall of cimetidine and, whilst it is still used, it is no longer amongst the more widely used H₂-receptor antagonists. Cimetidine should be used with caution is causes of hepatic impairment and cardiovascular disease. Side effects can include dizziness, and more rarely, headache. BIOAVAILABILITY: The observed bioavailibility of cimetidine is almost 60%.

References

• Michnovicz JJ, Galbraith RA .Cimetidine inhibits catechol estrogen metabolism in women. Metabolism. 1991 Feb;40(2):170-4. PMID 1988774

Template:H2-receptor antagonist